Tumor-infiltrating plasma cell targets as a source for immunotherapies.

Tumor-infiltrating plasma cells targeting citrullinated proteins enable effective CAR T-cell therapies in lung cancer.

• Why it matters: Understanding plasma cell responses in tumors can unlock new immunotherapy strategies, especially for patients resistant to current treatments like anti-PD-1.
• What they did: Meyerhoff et al. analyzed plasma cells from lung tumor lesions of anti-PD-1-treated patients and engineered CAR T cells with their scFv, demonstrating tumor-specific activity.
• The result: This approach shows promise for developing targeted immunotherapies with high specificity and minimal adverse effects, advancing personalized cancer treatment.